Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T22:26:40.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016

Published online by Cambridge University Press:  16 December 2019

Carsten Hjorthøj Open the ORCID record for Carsten Hjorthøj [Opens in a new window] ,
Maria Oku Larsen ,
Marie Stefanie Kejser Starzer  and
Merete Nordentoft
Carsten Hjorthøj*
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark
Maria Oku Larsen
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Marie Stefanie Kejser Starzer
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
Merete Nordentoft
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
*
Author for correspondence: Carsten Hjorthøj, E-mail: Carsten.hjorthoej@regionh.dk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Worldwide, cannabis is the most used illegal substance, and the use of cannabis has increased over the years. An increase in the level of tetrahydrocannabinol (THC) in cannabis has also been seen. It is currently unclear whether this has led to an increase in the incidence of cannabis-induced psychosis. We aimed to investigate (1) the development of incidence of cannabis-induced psychosis over time compared with other substance-induced psychoses and (2) the development of incident cases of cannabis-induced psychosis over time compared with dual diagnosis defined as schizophrenia and a cannabis use disorder.

Method

Data on psychiatric diagnoses were extracted from the Danish Psychiatric Central Research Register and summarized per year as both absolute incidence (number of cases) and incidence rates per 100 000 person years.

Results

The incidence rate of cannabis-induced psychosis increased steadily from 2.8 per 100 000 person years in 2006 to 6.1 per 100 000 person years in 2016. There was a corresponding increase in dual diagnosis with schizophrenia and cannabis use disorder, but a decrease in alcohol-induced psychosis. The data showed no trend in the other substance-induced psychosis investigated in this thesis.

Conclusion

The increase in cannabis-induced psychosis follows both the increase in the level of THC in cannabis, and the increase in cannabis use. The change in diagnostic practice does not appear to explain the increase in incidence of cannabis-induced psychosis.

Keywords

Cannabis use disordercannabis-induced psychosisdual diagnosisincidenceschizophreniasubstance-induced psychosis
Type
Original Article
Information
Psychological Medicine , Volume 51 , Issue 4 , March 2021 , pp. 617 - 622
Check for updates
Copyright
Copyright © Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arendt, M., Rosenberg, R., Foldager, L., Perto, G., & Munk-Jørgensen, P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. The British Journal of Psychiatry: the Journal of Mental Science, 187, 510–515.CrossRefGoogle ScholarPubMed
Carey, C. E., Agrawal, A., Bucholz, K. K., Hartz, S. M., Lynskey, M. T., Nelson, E. C., … Bogdan, R. (2016). Associations between polygenic risk for psychiatric disorders and substance involvement. Frontiers in genetics, 7, 149.CrossRefGoogle ScholarPubMed
Carliner, H., Brown, Q. L., Sarvet, A. L., & Hasin, D. S. (2017). Cannabis use, attitudes, and legal status in the U.S.: A review. Preventive Medicine 104, 13–23.CrossRefGoogle ScholarPubMed
Caton, C. L. M., Samet, S., & Hasin, D. S. (2000). When acute-stage psychosis and substance use co-occur: Differentiating substance-induced and primary psychotic disorders. Journal of Psychiatric Practice, 6, 256–266.CrossRefGoogle ScholarPubMed
European Monitoring Centre for Drugs and Drug Addiction (2019). European Drug Report 2019. Retrieved December 6, 2019, from http://www.emcdda.europa.eu/edr2019_enGoogle Scholar
Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., … Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet Psychiatry, 2, 233–238.CrossRefGoogle ScholarPubMed
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., … EU-GEI WP2 Group (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. The Lancet. Psychiatry 6, 427–436.CrossRefGoogle ScholarPubMed
Freeman, T. P., Groshkova, T., Cunningham, A., Sedefov, R., Griffiths, P., & Lynskey, M. T. (2019). Increasing potency and price of cannabis in Europe, 2006–16. Addiction, 114, 1015–1023.CrossRefGoogle Scholar
Gage, S. H., Hickman, M., & Zammit, S. (2016). Association between cannabis and psychosis: Epidemiologic evidence. Biological Psychiatry, 79, 549–556.CrossRefGoogle ScholarPubMed
Hansen, S. S., Munk-Jorgensen, P., Guldbaek, B., Solgard, T., Lauszus, K. S., Albrechtsen, N., … Bertelsen, A. (2000). Psychoactive substance use diagnoses among psychiatric in-patients. Acta Psychiatrica Scandinavica, 102, 432–438.CrossRefGoogle ScholarPubMed
Hiemstra, M., Nelemans, S. A., Branje, S., van Eijk, K. R., Hottenga, J.-J., Vinkers, C. H., … Boks, M. P. (2018). Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence. Drug and Alcohol Dependence, 190, 143–150.CrossRefGoogle ScholarPubMed
Hjorthøj, C., Uddin, M. J., Wimberley, T., Dalsgaard, S., Hougaard, D. M., Børglum, A., … Nordentoft, M. (2019). No evidence of associations between genetic liability for mental disorders and cannabis use disorder in people with and without schizophrenia. Psychological Medicine. In press.Google ScholarPubMed
Kendler, K. S., Ohlsson, H., Sundquist, J., & Sundquist, K. (2019). Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish National Sample. American Journal of Psychiatry, 176, 711–719.CrossRefGoogle Scholar
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42, 1262–1269.CrossRefGoogle ScholarPubMed
Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., & Lewis, G.(2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, 319–328.CrossRefGoogle ScholarPubMed
Morrison, P. D., Zois, V., McKeown, D. A., Lee, T. D., Holt, D. W., Powell, J. F., … Murray, R. M. (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 39, 1607–1616.CrossRefGoogle ScholarPubMed
Mors, O., Perto, G. P., & Mortensen, P. B. (2011). The Danish Psychiatric Central Research Register. Scandinavian Journal of Public Health, 39, 54–57.CrossRefGoogle ScholarPubMed
Nielsen, S. M., Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. (2017). Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: A nationwide population based register study. Psychological Medicine, 47, 1–10.CrossRefGoogle ScholarPubMed
Pedersen, C. B., Gøtzsche, H., Møller, J. O., & Mortensen, P. B. (2006). The Danish Civil Registration System. A cohort of eight million persons. Danish Medical Bulletin, 53, 441–449.Google ScholarPubMed
Power, R. A., Verweij, K. J. H., Zuhair, M., Grant, W., Henders, A. K., Heath, A. C., … Martin, N. G. (2014). Genetic predisposition to schizofrenia associated with increased use of cannabis. Molecular Psychiatry, 19, 1201–1204.CrossRefGoogle Scholar
Sara, G. E., Burgess, P. M., Malhi, G. S., Whiteford, H. A., & Hall, W. C. (2014). The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. The Journal of Clinical Psychiatry, 75, 349–356.CrossRefGoogle ScholarPubMed
Starzer, M. S. K., Nordentoft, M., & Hjorthøj, C. (2018). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry, 175, 343–350.CrossRefGoogle ScholarPubMed
Sundhedsstyrelsen (n.d.). Narkotikasituationen i Danmark 2017. Retrieved December 6, 2019, from https://www.sst.dk/da/udgivelser/2017/~/media/AA63B6154AEA4587A773FC6DDD7FDA12.ashxGoogle Scholar
Verweij, K. J. H., Abdellaoui, A., Nivard, M. G., Sainz Cort, A., Ligthart, L., Draisma, H. H. M., … Vink, J. M. (2017). Short communication: Genetic association between schizophrenia and cannabis use. Drug and Alcohol Dependence, 171, 117–121.CrossRefGoogle ScholarPubMed